Lu, F., Gao, J., Ogawa, R., Hyakusoku, H
Athletes often report improved joint flexibility and reduced stiffness after TB500 use
These benefits were further supported by the results of the SUMMIT trial, which investigated tirzepatide, a dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist, in patients with HFpEF with or without T2D
The three most recent Phase 3 readouts are: TRIUMPH-4 (December 2025) showing 28.7% weight reduction at 68 weeks in obesity with knee osteoarthritis, TRANSCEND-T2D-1 (March 2026) showing A1C reductions up to 2.0% and 16.8% weight loss at 40 weeks in type 2 diabetes, and TRIUMPH-1 (May 2026) showing up to 25.0% weight reduction at 80 weeks in the pivotal obesity trial
At Aura Aesthetics, our medically supervised GLP-1 weight loss program combines science-backed medications with personal support to help you lose weight safely and sustainably
Adriani W et al